EUVIMEDEUVIMED entdecken
Kohortenstudie

Therapeutic Drug Monitoring of Imatinib and N ‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

Xiaoxing Huang, Yiwei Liu, Jie Chen, Heng Zheng, Yufeng Ding, Zheng He

The Journal of Clinical Pharmacology · 2023

DOI: 10.1002/jcph.2329 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Xiaoxing Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Transfusion, Zhongnan Hospital of Wuhan University, Wuhan, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imatinib is an oral tyrosine kinase inhibitor (TKI) and first‐line therapy for patients with chronic myeloid leukemia (CML). There is a positive correlation between serum imatinib concentrations and treatment response. However, the specific relationship between the blood concentration of imatinib and its influencing factors remains unclear. This study collected basic information from 102 patients using imatinib as first‐line treatment for CML. Further, we analyzed the individual differences in imatinib concentration and explored its influencing factors. Through intra‐day and inter‐day precision studies, we found that the precision for the imatinib assay methodology was within ±13% and that the recovery rate was above 85%. There is notable individual variation in the blood concentration of imatinib; the recommended treatment concentration is 860‐1500 ng/mL, with only 41.40% of patients achieving this concentration. Also, there was a negative correlation between age and imatinib trough concentration (C trough ), as is observed between age and N ‐desmethyl imatinib. Moreover, compared with the adolescent group, the serum imatinib C trough for groups aged 17‐47 and 48‐68 years was significantly reduced. Further analysis shows that imatinib C trough values reaching therapeutic concentrations (59%) increased dramatically for patients with CML aged 17‐47 years. Moreover, groups dosed with 400 mg/day resulted in therapeutic imatinib concentrations for 68% of patients with CML, which was the best performance. The established method was validated, with acceptable accuracy, precision, linearity, and stability, as required, and then successfully applied to the therapeutic drug monitoring of imatinib. Age, dose, and metabolites can influence the imatinib concentration and its therapeutic effect in patients with CML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAdolescentHumansImatinib MesylateChromatography, LiquidDrug MonitoringCohort StudiesTandem Mass SpectrometryProtein Kinase Inhibitors

Stichwörter der Autor:innen

LC-MS/MSTDMchronic myelogenous leukemiaimatinibindividualized medicationtyrosine kinase inhibitor

Substanzen

Imatinib MesylateAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Blood Transfusion, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Zitieren

APA

Huang, X., Liu, Y., Chen, J., Zheng, H., Ding, Y., & He, Z. (2023). Therapeutic Drug Monitoring of Imatinib and N ‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2329

Vancouver

Huang X, Liu Y, Chen J, Zheng H, Ding Y, He Z. Therapeutic Drug Monitoring of Imatinib and N ‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2329

BibTeX
@article{Huang2023,
  author = {Huang, Xiaoxing and Liu, Yiwei and Chen, Jie and Zheng, Heng and Ding, Yufeng and He, Zheng},
  title = {Therapeutic Drug Monitoring of Imatinib and N ‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study},
  journal = {The Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1002/jcph.2329}
}
Kostenlos starten →